ZL-1310 earns fast track designation in extensive-stage small cell lung cancer after early trial data showed tumor shrinkage ...

Nearly half of people with advanced cancer receive aggressive care at the end of life, a rate little changed from a decade ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the 'Company') announced that a new indication application (the 'Application') for the Company's trophoblast cell-surface antigen 2 (TROP2)-directed ...

We explored their survival using Kaplan–Meier analysis and Cox regression ... The well-established division of primary malignant tumours of the lung into small cell lung cancer (SCLC) and non-SCLC ...

"Dosing the first patient in the TNG456 Phase I/II trial marks a significant step for us and for patients with MTAP-deleted GBM," Adam Crystal, Tango's president of R&D, said in a statement. "People ...